BAYER AG NA O.N.
Commented by Carsten Mainitz on September 8th, 2021 | 12:28 CEST
PuriflOH, Bayer, Philips - Innovations as yield drivers
Innovations enrich our everyday lives in many ways. The following companies have developed innovative solutions for health and climate in the broadest sense that help remedy important problems. The focus here is on water, a scarce resource, and air purification, which in times of Corona plays an increasingly important role. Which Company has the best opportunities?
Read
Commented by Nico Popp on August 26th, 2021 | 10:41 CEST
BioNTech, Cardiol Therapeutics, Bayer: Where Covid-19 still provides returns
The pandemic has not only brought losers. There is also a long list of winners. Starting with Amazon and Deutsche Post and ending with BioNTech. Before Corona, the latter Company was always considered a beacon of hope around mRNA technology. Then came the pandemic, and suddenly several small test balloons turned into a gigantic project as we know it today, with a successful outcome. We shed light on BioNTech and also focus on other potential winners of the pandemic.
Read
Commented by André Will-Laudien on August 18th, 2021 | 10:43 CEST
Bayer, Cardiol Therapeutics, CureVac: The Champions League of Bio-Pharma!
Biopharmaceutics is the first port of call in the fight against a wide range of diseases. It studies the relationship between drugs and excipients' chemical and physical properties and their form of administration in a living organism. Biological effectiveness results from the entry of the drug into the diseased organism, its distribution in tissues, and the chemical reaction called metabolism. When dealing with recent pandemics, good advice is expensive, and research into pharmaceuticals costs billions. When an active ingredient is found and registered, the patent clock starts ticking for the inventor. As a result, the hope of the biopharmaceutical company is to remain the sole provider in their healing segment for as long as possible.
Read
Commented by Carsten Mainitz on August 17th, 2021 | 11:12 CEST
Memiontec, Bayer, Aurubis - Do not miss this trend!
According to estimates by some experts, water demand will already exceed supply by 40% in 2030. That is a dramatic forecast and should wake us up. Of course, climate change is an influencing factor. The increasing water consumption of agriculture in the wake of the growing population presents us with major challenges. In addition, water treatment plays a central role. Some promising investment ideas can be derived from the scarcity problem of the vital resource water.
Read
Commented by Stefan Feulner on August 6th, 2021 | 13:14 CEST
Bayer, Blackrock Silver, Siemens - Confidence is rising
After the months-long Corona lockdowns, the increasing desire for sports makes sporting goods manufacturer Adidas optimistic for the future. Online retailer Zalando also grew strongly in the second quarter, confirming growth forecasts. Companies' optimism is also reflected in the DAX, which could take a run-up to new highs for the year and the historic mark of 16,000 points, despite the summer months.
Read
Commented by Stefan Feulner on July 22nd, 2021 | 11:57 CEST
SAP, Deutsche Rohstoff, Bayer, Condor Gold - Better than expected
The reporting season for the second quarter of 2021 is in full swing. After the weak figures from the same period last year, caused by the Corona pandemic, analysts and investors expect significant earnings increases from companies that suffered heavy losses due to the global lockdowns. On the other hand, it will be interesting to see whether Corona beneficiaries such as Amazon can confirm their growth.
Read
Commented by Carsten Mainitz on July 20th, 2021 | 11:28 CEST
Mineworx Technologies, Siemens, Bayer - Innovation is the trump card
Since 2005, the Boston Consulting Group has annually selected the world's 50 most innovative companies. The list reads like a "Who's Who" of international heavyweights: Apple, Alphabet, Amazon, Microsoft and Tesla took the top 5 spots in 2021. In total, the United States was able to occupy 26 of the 50 spots - that is an impressive number. But German companies also find their way into the illustrious circle 9 times, including Siemens and Bayer. Why is innovation so important? Innovation is a key success factor for a company to achieve above-average results and differentiate itself from competitors. For this reason, we take a closer look at innovative companies in different industries. Who is your favorite?
Read
Commented by Armin Schulz on July 14th, 2021 | 10:54 CEST
Cardiol Therapeutics, CureVac, Bayer - Where is the journey heading?
One might think that the pharmaceutical industry is the big winner of the Corona Crisis. However, according to a study by EY, this is not the case. Sales did increase by an average of 4.4% at the largest pharma companies, a much better result than in many other industries, but compared to 2019, growth actually fell by 8.4%. That is due to the postponement of medical treatments due to the Corona Crisis. The industry benefits from the ever-increasing number of elderly people worldwide and, at the same time, the development of new drugs. As a result, sales and profits have increased even during the crisis. We, therefore, highlight three companies from the pharma sector.
Read
Commented by Stefan Feulner on July 13th, 2021 | 10:05 CEST
Bayer, Almonty Industries, Daimler - Shortages without end
The shortage of semiconductors weighs heavily on the auto industry. According to a study by the Duisburg-based Center for Automotive Research, it will be responsible for the loss of production of around five million vehicles this year alone. An end to the chip shortage is not yet in sight. Meanwhile, the next crisis due to the lack of raw materials is already just around the corner. Due to the rapid growth in electromobility, the high demand for lithium-ion batteries means that the next failures are pre-programmed.
Read
Commented by Nico Popp on July 6th, 2021 | 11:34 CEST
Bayer, XPhyto Therapeutics, Pfizer: Here comes the blockbuster of the 4th wave
Hygiene sluices, rapid tests, disinfectants and vaccines - what was more familiar to laboratory staff or doctors a few years ago has become our daily bread since the outbreak of the pandemic. It stands to reason that the new normality would also leave its mark on the stock market. Indeed, the shares of major pharmaceutical companies have already risen. However, there are still newcomers with considerable potential. Growth companies, in particular, could benefit from the hype surrounding hygiene and health.
Read